Lavanya Bellumkonda, MD
Associate Professor of Medicine (Cardiovascular Medicine)Cards
About
Research
Publications
2024
Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella
Rommel K, Bonnet G, Bellumkonda L, Lansky A, Zhao D, Thompson J, Zhang Y, Redfors B, Lurz P, Granada J, Bharadwaj A, Basir M, O'Neill W, Burkhoff D. Right Ventricular Dysfunction in Patients Undergoing High-Risk PCI with Impella. Journal Of Cardiac Failure 2024, 30: 1244-1254. PMID: 39389734, DOI: 10.1016/j.cardfail.2024.08.001.Peer-Reviewed Original ResearchConceptsRight ventricular dysfunctionHigh-risk percutaneous coronary interventionVentricular dysfunctionAssociated with right ventricular dysfunctionTricuspid annular plane systolic excursionConcomitant right ventricular dysfunctionLower left ventricular ejection fractionUnfavorable long-term prognosisAnnular plane systolic excursionClinical outcomes of patientsAbsence of right ventricular dysfunctionImpella supportPredictor of 1-year mortalityMultivariate Cox regression analysisIncidence of hypotensive episodesEchocardiography core laboratorySevere RV dilatationBlood urea nitrogen levelsRV function assessmentVentricular ejection fractionOutcomes of patientsRates of in-hospital mortalityHigher blood urea nitrogen levelsLong-term prognosisProportion of patientsClinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI
Abu-Much A, Grines C, Chen S, Batchelor W, Zhao D, Falah B, Maini A, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Zhang Y, Zhou Z, Baron S, Lansky A, Basir M, O'Neill W, Cohen D. Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI. International Journal Of Cardiology 2024, 417: 132555. PMID: 39270940, DOI: 10.1016/j.ijcard.2024.132555.Peer-Reviewed Original ResearchLower left ventricular ejection fractionMitral valve regurgitationPercutaneous coronary interventionHigh-risk PCISevere MRHigh-risk percutaneous coronary interventionMR severityPCI-related complicationsValve regurgitationIII studiesHeart failureAssociated with worse outcomesPrevalence of heart failurePresence of severe MRLower body mass indexVentricular ejection fractionStatistical significanceHigh-risk PCI patientsBody mass indexTrace MREjection fractionModerate MRClinical outcomesMild MRWorse outcomesMechanistic Differences between Torsemide and Furosemide.
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024 PMID: 39196651, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightSurveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry
Khush K, Hall S, Kao A, Raval N, Dhingra R, Shah P, Bellumkonda L, Ravichandran A, Van Bakel A, Uriel N, Patel S, Pinney S, DePasquale E, Baran D, Pinney K, Oreschak K, Kobulnik J, Shen L, Teuteberg J. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry. The Journal Of Heart And Lung Transplantation 2024, 43: 1409-1421. PMID: 38759766, DOI: 10.1016/j.healun.2024.05.003.Peer-Reviewed Original ResearchAcute cellular rejectionIncidence of acute cellular rejectionBiopsy rateGene expression profilesNon-invasive testsMolecular testingDd-cfDNACellular rejectionGraft dysfunctionHeart transplantationFollow-up testing ratesIncidence of graft dysfunctionLow biopsy rateFollow-up biopsiesPositive likelihood ratioNon-invasive surveillanceBiopsy dataClinical decision-makingExcellent survivalOutcomes RegistryFollow-upLow incidenceBiopsyPositive groupDual testingHigh- versus low-gradient aortic stenosis: Is our evaluation limited by aorto-mitral angle on cardiovascular CT?
See C, Kim Y, Park J, Wang Y, Reinhardt S, Shkolnik E, Faridi K, Lombo B, Bellumkonda L, McNamara R, Sugeng L, Hur D. High- versus low-gradient aortic stenosis: Is our evaluation limited by aorto-mitral angle on cardiovascular CT? International Journal Of Cardiology 2024, 409: 132174. PMID: 38754590, DOI: 10.1016/j.ijcard.2024.132174.Peer-Reviewed Original ResearchNormal-flow low-gradientAortic valve areaTranscatheter AV replacementParadoxical low-flow low-gradientCardiovascular CTTransthoracic echocardiogramCalcium scoreAS patientsDiagnosis of severe ASLow-gradient aortic stenosisHG-AS patientsLG-AS patientsLow-flow low-gradientAorto-mitral angleAortic valve (AV) stenosisLG-ASPLFLG-ASAV replacementSevere ASConsecutive patientsAortic stenosisValve areaAS phenotypeClinical managementEchocardiogramThree-dimensional (3D) Right Ventricular Surface Strain Computed From 3D Echocardiography Correlates With RVEF and Reveals Differences in Deformation Based on Severity of Pulmonary Arterial Hypertension Symptoms
Oakland H, Bellumkonda L, Sugeng L, Joseph P, Izzi D, Zalik F, McCabe S, Raza A, Amendola R, Heerdt P, Singh I, Hunter K. Three-dimensional (3D) Right Ventricular Surface Strain Computed From 3D Echocardiography Correlates With RVEF and Reveals Differences in Deformation Based on Severity of Pulmonary Arterial Hypertension Symptoms. 2024, a7381-a7381. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7381.Peer-Reviewed Original Research(1118) Impact of Induction Therapy on Gene Expression Profiling and Donor Derived Cell Free DNA
Dhingra R, Bellumkonda L, Vaidya A, Chen L, Jawaid A, Czinn E, Pinney K, Wang S, Patel S, Jenkins L, DePasquale E, Guha A, Uriel N. (1118) Impact of Induction Therapy on Gene Expression Profiling and Donor Derived Cell Free DNA. The Journal Of Heart And Lung Transplantation 2024, 43: s519-s520. DOI: 10.1016/j.healun.2024.02.735.Peer-Reviewed Original ResearchSerial direct sodium removal in patients with heart failure and diuretic resistance
Rao V, Ivey‐Miranda J, Cox Z, Moreno‐Villagomez J, Ramos‐Mastache D, Neville D, Balkcom N, Asher J, Bellumkonda L, Bigvava T, Shaburishvili T, Bartunek J, Wilson F, Finkelstein F, Maulion C, Turner J, Testani J. Serial direct sodium removal in patients with heart failure and diuretic resistance. European Journal Of Heart Failure 2024, 26: 1215-1230. PMID: 38556717, DOI: 10.1002/ejhf.3196.Peer-Reviewed Original ResearchConceptsDiuretic resistanceCardiorenal syndromeHeart failureLoop diureticsDiuretic withdrawalHigh-dose loop diureticsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideGrowth differentiation factor 15Carbohydrate antigen 125Differentiation factor 15Sodium removalRandomized controlled studyCardiorenal parametersDiuretic doseSoluble ST2Natriuretic peptideMedian timeDiuretic responseKidney injuryPeritoneal membraneElectrolyte handlingKidney functionDiureticsInterleukin-6
2023
Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI
Abu-Much A, Grines C, Batchelor W, Maini A, Zhang Y, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Li Y, Baron S, Lansky A, Basir M, Cohen D, O'Neill W. Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI. American Heart Journal 2023, 269: 139-148. PMID: 38151142, DOI: 10.1016/j.ahj.2023.12.015.Peer-Reviewed Original ResearchBaseline LV ejection fractionLV ejection fractionPercutaneous coronary interventionPCI-related complicationsLV dysfunctionEjection fractionLV functionLeft main percutaneous coronary interventionHigh-risk percutaneous coronary interventionHigh-risk PCI patientsImmediate percutaneous coronary interventionMain percutaneous coronary interventionModerate LV dysfunctionSevere LV dysfunctionVentricular systolic dysfunctionVentricular ejection fractionCoronary complicationsLVEF groupMACCE rateCerebrovascular eventsPCI patientsSystolic dysfunctionCoronary interventionIII studyMyocardial infarctionEmpagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects
Rao V, Ivey-Miranda J, Cox Z, Moreno-Villagomez J, Maulion C, Bellumkonda L, Chang J, Field M, Wiederin D, Butler J, Collins S, Turner J, Wilson F, Inzucchi S, Wilcox C, Ellison D, Testani J. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects. Journal Of The American Society Of Nephrology 2023, 35: 189-201. PMID: 38073038, PMCID: PMC10843196, DOI: 10.1681/asn.0000000000000269.Peer-Reviewed Original Research
Clinical Trials
Current Trials
MitraClip REPAIR MR Study
HIC ID2000031013RoleSub InvestigatorPrimary Completion Date02/28/2024Recruiting ParticipantsGenderBothAge18+ yearsRandomized Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
HIC ID2000028335RolePrincipal InvestigatorPrimary Completion Date01/27/2025Recruiting ParticipantsGenderBothAge18+ yearsErtugliflozin in Acute Heart Failure
HIC ID2000027951RoleSub InvestigatorPrimary Completion Date01/31/2022Recruiting ParticipantsGenderBothAge18+ yearsTranscatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation (APOLLO)
HIC ID2000021883RoleSub InvestigatorPrimary Completion Date10/31/2021Recruiting ParticipantsGenderBothAge18+ yearsTranscatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
HIC ID2000021341RoleSub InvestigatorPrimary Completion Date12/31/2021Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
Clinical Care
Overview
As a cardiologist who specializes in advanced heart failure and transplantation, Lavanya Bellumkonda, MD, says offering hope is key when she first meets a patient.
“When someone hears the term ‘heart failure,’ they may think they are dying imminently. I first review the severity of their disease and try to set realistic expectations. A number of patients with heart failure will have improvement in their cardiac function with appropriate medical therapy,” she explains. “If their disease is advanced, they may need a mechanical pump to assist the heart or a heart transplantation, and we discuss the success rates and risks associated with each of these strategies.”
Heart failure describes any kind of dysfunction in the heart that causes a build-up of fluids, resulting in shortness of breath, fatigue, and swelling in the legs. Dr. Bellumkonda says she was drawn to her field because of her fascination with the physiology of the heart and the acuity of cardiac illnesses.
“What I also like about transplant cardiology is that you get to apply all that you learnt in medicine and cardiology,” she says. “Post-transplant, patients often rely on me to manage their medical conditions as well.”
Additionally, Dr. Bellumkonda treats patients with valve disease. “The most common valves affected are the mitral or aortic valves, where these valves get either too tight or too leaky, causing symptoms similar to heart failure,” she says. “At Yale, we treat these patients in a multidisciplinary fashion and provide appropriate recommendations regarding catheter-based interventions and surgery.”
Her research interests include cardiac recovery and cardio-renal reactions in patients with valve disease. “What makes me most happy in my work is when I have cardiac recovery in my patients, meaning they have an improvement in their heart function,” she says. “That makes me feel like I have done my job.”
Clinical Specialties
Fact Sheets
Ventricular Assist Device (VAD)
Learn More on Yale MedicineCongestive Heart Failure (CHF)
Learn More on Yale MedicineHeart Failure Surgery
Learn More on Yale MedicineExtracorporeal Membrane Oxygenation (ECMO)
Learn More on Yale Medicine
Board Certifications
Cardiovascular Disease
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2008
Yale Medicine News
News & Links
News
- July 13, 2023
Department of Internal Medicine Promotions and Appointments (July 2023)
- April 08, 2022
Study Unlocks Key to Improved Outcomes for Heart Transplant Recipients
- January 31, 2020Source: HCM Beat
Patients Fare Best at HCM Specialty Centers
- December 10, 2018Source: Healio
Intra-aortic balloon implantation decreases mortality risk in cardiogenic shock